Download citation file:
From Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts.
Acknowledgments: The authors are indebted to the 39 876 participants in the Women's Health Study for their dedicated and conscientious collaboration and to the entire staff of the study. They also thank Roche Molecular Systems for providing the genotyping platform used in the study.
Grant Support: By the National Institutes of Health (grants HL71221, HL43851, and CA47988). Natural Source Vitamin E Association provided the vitamin E and vitamin E placebo, and Bayer HealthCare provided the aspirin and placebo aspirin.
Potential Financial Conflicts of Interest: Grants received: R.J. Glynn (Bristol-Myers Squibb). Honoraria: J.E. Buring (Bayer HealthCare). Other: J.E. Buring (Bayer HealthCare, Natural Source Vitamin E Association).
Requests for Single Reprints: Robert J. Glynn, PhD, ScD, Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue, Boston, MA 02215; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Glynn, Ridker, and Buring: Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue, Boston, MA 02215.
Dr. Goldhaber: Division of Cardiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115.
Author Contributions: Conception and design: R.J. Glynn, P.M. Ridker, J.E. Buring.
Analysis and interpretation of the data: R.J. Glynn, P.M. Ridker, S.Z. Goldhaber, J.E. Buring.
Drafting of the article: R.J. Glynn.
Critical revision of the article for important intellectual content: R.J. Glynn, P.M. Ridker, S.Z. Goldhaber, J.E. Buring.
Final approval of the article: R.J. Glynn, P.M. Ridker, S.Z. Goldhaber, J.E. Buring.
Provision of study materials or patients: J.E. Buring.
Statistical expertise: R.J. Glynn.
Obtaining of funding: R.J. Glynn, J.E. Buring.
Collection and assembly of data: R.J. Glynn, P.M. Ridker, J.E. Buring.
In this large-scale, long-term trial of initially healthy women, 100 mg of aspirin on alternate days had little association with the overall rate of VTE and the rate of unprovoked VTE. The association of low-dose aspirin with the hazard of VTE was uniform during treatment and did not vary substantially across subgroups. No clear benefit of aspirin was observed among subgroups at particularly high risk for VTE who might benefit most from preventive therapies, although 95% CIs in some subgroups were wide.
WHS = Women's Health Study.
A. Incidence of total VTE (P = 0.58, log-rank test). B. Incidence of unprovoked VTE (P = 0.48, log-rank test) C. Incidence of VTE in women with a history of VTE at baseline (P = 0.33, log-rank test) D. Incidence of VTE in women without a history of VTE at baseline (P = 0.32, log-rank test).
BMI = body mass index; HT = hormone therapy; VTE = venous thromboembolism.
Please read the other comments before posting. Contributors must reveal any conflict
Comments are moderated and will appear on the site at the discretion of The American
College of Physicians editorial staff. Please be sure your email address is
updated in your account, otherwise the American College of Physicians will not be
able to contact you about your comment.
Anyone can submit a comment any time after publication, but only those submitted within 4 weeks of an article’s publication will be considered for print publication. One month after publication, editors review all posted comments and select some for publication in the Letters section of the print version of Annals. (Not peer reviewed)
Authors: No more than 5
Text: Word Limit 400 (excludes references), 5 references, no figures or tables
* = Required Field
Disclosure of Any Conflicts of Interest*
(applies to the past 5 years and foreseeable future) Indicate any potential conflicts
of interest of each author below, including specific financial interests and relationships
and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers
bureau, stock ownership or options, expert testimony, royalties, donation of medical
equipment, or patents filed, received, or pending). If all authors have none, check
"No potential conflicts or relevant financial interests" in the box below. Please
also indicate any funding received in support of this work. The information will
be posted with your response.
Aspirin and other antiplatelet drugs are highly effective at reducing major vascular events in patients who are at risk for or who have established atherosclerotic disease.1 Evidence suggests that antiplatelet agents can lower the risk for venous thromboembolism (VTE) in high-risk patients.2 Why aspirin is not effective for primary prevention of VTE in women at low to moderate risk as seen in the present study? Part of the answer to this question may be found in the differences in thrombus formation between the arterial and venous systems. The low-flow and low- pressure venous system is susceptible to reduced blood flow (stasis) and systemic activation of the coagulation cascade, as Virchow described more than 150 years ago, which predisposes to a thrombus even in a nonstenotic vessel. Most venous thrombi consist predominantly of red cells enmeshed in fibrin and contain relatively few platelets; hence, they have been described pathologically as "red thrombi." In contrast, in the high-flow and high-pressure arterial system, thrombi form under the influence of local shear forces, platelet activation, and exposure to thrombogenic substances on damaged vascular surfaces. Arterial thrombi, referred to as "white thrombi," typically are composed predominantly of platelets with relatively little fibrin or red-cell accumulation. Thus, it is plausible to expect that an anticoagulant would be used to prevent venous thromboemboli, whereas an antiplatelet agent would be used to prevent arterial thrombosis.3
1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308:235"“246
2. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial. Lancet 2000; 355:1295"“1302
3. Richard N. Mitchell : Hemodynamic Disorders, Thromboembolic Disease, and Shock in Robbins and Cotran Pathologic Basis Of Disease 7th Ed. Saunders. 2004 pp119-144
Occurrence of Venous Thromboembolism in Women Taking Low-Dose Aspirin
The summary below is from the full report titled “Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism. A Randomized Trial.” It is in the 16 October 2007 issue of Annals of Internal Medicine (volume 147, pages 525-533). The authors are R.J. Glynn, P.M Ridker, S.Z. Goldhaber, and J.E. Buring.
The In the Clinic® slide sets are owned and copyrighted by the American College
of Physicians (ACP). All text, graphics, trademarks, and other intellectual property
incorporated into the slide sets remain the sole and exclusive property of the ACP.
The slide sets may be used only by the person who downloads or purchases them and
only for the purpose of presenting them during not-for-profit educational activities.
Users may incorporate the entire slide set or selected individual slides into their
own teaching presentations but may not alter the content of the slides in any way
or remove the ACP copyright notice. Users may make print copies for use as hand-outs
for the audience the user is personally addressing but may not otherwise reproduce
or distribute the slides by any means or media, including but not limited to sending
them as e-mail attachments, posting them on Internet or Intranet sites, publishing
them in meeting proceedings, or making them available for sale or distribution in
any unauthorized form, without the express written permission of the ACP. Unauthorized
use of the In the Clinic slide sets will constitute copyright infringement.
to gain full access to the content and tools.
Learn more about subscription options